A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer

Summary

This trial studies how well the drug tucatinib works when given with trastuzumab deruxtecan (T-DXd). It will also look at what side effects happen when these drugs are given together. A side effect is anything a drug does besides treating cancer. Participants in this trial have HER2-positive (HER2+) breast cancer that has either spread to other parts of the body (metastatic) or cannot be removed completely with surgery (unresectable). All participants will get both tucatinib and T-DXd.

Timeline

Start

2020-12-01

Primary completion

2024-07-15

Completion

2025-03-07

Publications

• Modi S, Murthy RK, Chien AJ, Lin NU, McAndrew NP, Specht JM, Zelnak AB, Ramos J, Xie D, Ho J, Inoue JK, Carey LA, Hamilton EP. Tucatinib in Combination With Trastuzumab Deruxtecan in Patients With Previously Treated HER2+ Unresectable Locally Advanced or Metastatic Breast Cancer: An Open-Label Phase 2 Study. Clin Breast Cancer. 2026 Jul 10;26(8):21-30. doi: 10.1016/j.clbc.2026.05.010. Online ahead of print.

Drugs

Indications